What You Should Know
- Analytical and clinical laboratory technology giant Agilent Technologies Inc. announced that it has entered into a definitive agreement to acquire digital pathology software and AI company Proscia®.
- Transaction financial terms: an all-cash acquisition valued at $240M in cash at closing, plus up to an additional $30M contingent on achieving future operational and financial performance milestones (total potential deal value of $270M).
- Closes the loop on a four-year commercial partnership: Agilent and Proscia originally entered into a multi-year global distribution agreement in September 2022 to co-market an open digital diagnostic pathology ecosystem.
- Unifies an end-to-end precision medicine triad: merges Agilent’s established portfolio of automated slide stainers, pathology instrumentation, diagnostic reagents, and companion diagnostics (CDx) with Proscia’s vendor-agnostic enterprise software platform, Concentriq®, which serves as an operational orchestration layer across scanners, LIS networks, and AI algorithms.
Assembling the Full Pathology Stack
By acquiring Proscia, Agilent secures the missing software operating system. Instead of selling discrete instruments and reagents, Agilent can now deliver an end-to-end ecosystem: tissue preparation reagents, automated staining instrumentation, vendor-neutral whole-slide ingestion, and regulatory-cleared diagnostic software.
Agilent and Proscia originally entered into a multi-year global distribution agreement in September 2022 to co-develop and sell integrated diagnostic pathology workflows. Acquiring Proscia transitions an external commercial alliance into an owned intellectual property core.
Agilent is a primary diagnostic partner for global pharma, co-developing FDA-approved companion diagnostic tests that determine patient eligibility for targeted cancer immunotherapies. Integrating Concentriq gives Agilent a direct digital data conduit into 16 of the top 20 biopharmas, creating an R&D feedback loop that unites prospective biomarker discovery with downstream clinical commercialization.
Transaction Economics & Target Operating Benchmarks
The acquisition brings a high-margin, recurring-revenue software foundation into Agilent’s diagnostic portfolio:
- Valuation Multiple & Purchase Price: Agilent is deploying $240M in cash at closing plus up to $30M in earnouts against Proscia’s trailing twelve months (TTM) revenue exceeding $18M —representing an upfront enterprise value-to-revenue multiple of approximately 13.3x (expanding to 15.0x including full earnouts), reflecting high market demand for enterprise software operating layers in diagnostics.
- Commercial Scale and Penetration: Proscia’s platform—anchored by its flagship Concentriq® software—is deployed across more than 4,000 laboratories, hospital systems, and clinics across North America and Europe.
- Top-Tier Biopharma Validation: Proscia software currently supports translational research and trial operations for 16 of the top 20 global pharmaceutical companies.
- Clinical Performance Benchmarks: Proscia earned 2026 Best in KLAS for Digital Pathology (securing the highest vendor performance score across both U.S. and European markets) and holds U.S. FDA 510(k) clearance for primary clinical diagnosis.
“Digital pathology is quickly becoming the foundation for pathology data generation, analysis, and application across biopharmaceutical research, clinical development, and diagnostics, and our acquisition of Proscia meaningfully expands our presence in this fast-growing market,” said Padraig McDonnell, President and CEO of Agilent. “The acquisition establishes an Agilent platform for scientific intelligence in tissue-based precision medicine, connecting data generation with AI-based interpretation in a workflow that supports biomarker research through routine clinical use. With Proscia’s leading platform and talented team, we will be better equipped to help laboratories and biopharma customers manage and derive insights from pathology data.”
